The White House Council of Economic Advisers announced a Most-Favored-Nation drug pricing framework aimed at lowering prescription medicine costs in the United States through international price benchmarking and voluntary agreements with major pharmaceutical manufacturers. The policy, released in May 2026, includes proposed Medicaid and Medicare reforms, direct-to-consumer pricing initiatives, and projected long-term savings exceeding $500 billion according to White House estimates.
The policy framework expands the Trump administration’s effort to align US branded drug prices with prices paid in other high-income countries. According to the Council of Economic Advisers, the initiative is designed to reduce healthcare spending while encouraging foreign governments to contribute more toward global pharmaceutical research and development costs.
MFN Drug Pricing Framework Overview
The White House said the framework is built around “Most-Favored-Nation” pricing, which ties US drug prices to international benchmarks across selected developed economies. The Council of Economic Advisers stated that the administration has already reached voluntary pricing agreements with 17 pharmaceutical manufacturers covering branded drugs and biologics.
The framework distinguishes between future drug launches and medicines already on the market. According to the report, new drugs introduced in the United States would be expected to launch at prices comparable to those paid in countries including the United Kingdom, Germany, France, Japan, Canada, Switzerland, and Denmark.
Key elements of the policy framework
The White House stated that the policy uses net international pricing rather than list prices, incorporating manufacturer rebates and discounts into the calculation.
The administration said the pricing structure is intended to operate alongside US trade policy efforts targeting pharmaceutical pricing systems in foreign markets.
| Indicator | Recent Movement | Context |
|---|---|---|
| Manufacturer agreements | 17 voluntary agreements reached | The White House Council of Economic Advisers said agreements were secured with major pharmaceutical manufacturers |
| Projected savings | $529 billion over 10 years | The Council of Economic Advisers estimated savings from prospective MFN pricing for future drug launches |
| Market scope | Private and public sectors included | The framework applies across Medicaid, Medicare, and commercial insurance markets according to the White House report |
Medicaid And Medicare Policy Changes
The administration said the framework includes new Medicaid pricing provisions for single-source branded drugs and biologics. According to the Council of Economic Advisers, manufacturers participating in voluntary agreements would provide Medicaid programs with Most-Favored-Nation pricing where current net prices exceed international benchmarks.
However, the report noted that certain Medicaid products already receive lower post-rebate pricing under existing federal rebate structures. The White House stated that the revised framework primarily targets higher-cost products concentrated within specialty drug categories.
Estimated healthcare savings and fiscal impact
According to the Council of Economic Advisers, projected Medicaid savings could reach $64.3 billion over 10 years, including both federal and state reductions in drug spending. Additionally, the White House said lower pricing for anti-obesity drugs could support expanded Medicare access to GLP-1 treatments through proposed demonstration programs beginning in July 2026.
- Federal savings: The Council of Economic Advisers estimated approximately $36.6 billion in federal Medicaid savings over 10 years
- State savings: State governments were projected to save roughly $27.6 billion under the proposed pricing framework
- GLP-1 access: The White House said future Medicare coverage expansion would use negotiated pricing to limit patient costs
TrumpRx.gov And Consumer Drug Pricing
The administration also announced expanded use of TrumpRx.gov, a direct-to-consumer pharmaceutical pricing platform designed to connect patients with manufacturer discount programs. According to the White House report, 16 of the 17 participating pharmaceutical companies had integrated pricing offers into the platform as of April 2026.
The framework places significant focus on GLP-1 obesity medications and fertility treatments, which often lack broad insurance coverage in the United States. The White House said negotiated pricing reductions are intended to lower direct patient spending outside traditional insurance systems.
Examples of patient savings under the program
The Council of Economic Advisers reported that some injectable GLP-1 medications declined from monthly prices exceeding $1,000 to approximately $350 through the direct-purchase platform. Fertility treatment medication costs associated with in-vitro fertilization cycles were projected to decline by several thousand dollars per treatment cycle.
| Indicator | Recent Movement | Context |
|---|---|---|
| GLP-1 monthly pricing | Reduced to about $350 | The White House said negotiated direct-to-consumer pricing lowered costs for obesity medications |
| IVF medication costs | Estimated savings above $2,000 per cycle | The Council of Economic Advisers cited lower fertility drug pricing through participating manufacturers |
| Projected consumer savings | Up to $3,000 annually | The White House estimated long-term annual savings for uninsured GLP-1 users |
International Trade And Pharmaceutical Pricing Pressure
The White House said the framework is designed to work alongside broader trade negotiations involving pharmaceutical pricing systems in allied countries. According to the Council of Economic Advisers, the administration intends to encourage foreign governments to contribute more toward global pharmaceutical research costs.
Additionally, the report argued that the United States currently bears a disproportionate share of global drug development financing due to higher domestic prices. The administration stated that international price convergence would involve both lower US pricing and higher pricing in certain foreign healthcare systems.
Potential impact on global pharmaceutical markets
The report cited recent pharmaceutical pricing arrangements between the United States and the United Kingdom as part of the broader strategy. The White House said pharmaceutical manufacturers could gain leverage in negotiations with foreign governments under the revised pricing environment.
- Trade linkage: The White House connected pharmaceutical pricing policy with broader US trade negotiations involving allied economies
- International pressure: The Council of Economic Advisers said foreign governments may face pressure to increase pharmaceutical spending
- Industry positioning: The White House stated that global research funding burdens would become more balanced over time
Administration Position On Innovation And Drug Development
The White House argued that the MFN framework is designed to preserve pharmaceutical innovation while redistributing research and development costs more evenly across developed countries. According to the Council of Economic Advisers, the administration does not view the framework as reducing global pharmaceutical revenue overall.
The report highlighted several Food and Drug Administration initiatives involving artificial intelligence-assisted reviews and Bayesian clinical trial methodologies. The White House said these efforts are intended to streamline drug approvals and reduce development costs for manufacturers.
Stakeholder comments and policy comparisons
The Council of Economic Advisers compared the MFN framework with previous drug pricing policies implemented under the Inflation Reduction Act. According to the White House report, the administration believes its framework provides broader market coverage and faster consumer price reductions than prior federal pricing reforms.
Additionally, the report said that the framework aims to avoid undermining pharmaceutical innovation incentives while still reducing domestic healthcare spending. However, long-term savings projections remain dependent on future international negotiations, manufacturer participation, and implementation outcomes.
The White House Most-Favored-Nation drug pricing framework represents a major expansion of federal efforts to reshape pharmaceutical pricing in the United States. The proposal combines healthcare policy, trade negotiations, and consumer drug pricing reforms within a broader attempt to reduce long-term prescription costs.
The framework is likely to face continued scrutiny from pharmaceutical manufacturers, healthcare providers, insurers, and foreign governments as negotiations and implementation efforts continue through 2026.
Sources: White House, Council of Economic Advisers, TrumpRx.gov.
Prepared by Ivan Alexander Golden, Founder of THX News, an independent news organization delivering timely insights from global official sources.
Research combines AI-assisted analysis with human-edited accuracy and context.
